These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24857351)

  • 41. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
    Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
    Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Feature analysis of IDH1 mutation in oligodendroglial tumors].
    Ren XH; Cui XL; Shang ZM; Lin S
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(11):724-6. PubMed ID: 22781348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
    Dougherty MJ; Santi M; Brose MS; Ma C; Resnick AC; Sievert AJ; Storm PB; Biegel JA
    Neuro Oncol; 2010 Jul; 12(7):621-30. PubMed ID: 20156809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A high-grade glioma with
    Vidal B; Bryke C; Hsu N; Alterman R; Yeo AT; Charest A; Varma H
    Clin Neuropathol; 2020; 39(3):126-134. PubMed ID: 31841105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRAF V600E mutation in epilepsy-associated glioneuronal tumors: Prevalence and correlation with clinical features in a Chinese population.
    Zhang YX; Shen CH; Guo Y; Zheng Y; Zhu JM; Ding Y; Tang YL; Wang S; Ding MP
    Seizure; 2017 Feb; 45():102-106. PubMed ID: 27984807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
    Purkait S; Bansal S; Malgulwar PB
    Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors.
    Prabowo AS; Iyer AM; Veersema TJ; Anink JJ; Schouten-van Meeteren AY; Spliet WG; van Rijen PC; Ferrier CH; Capper D; Thom M; Aronica E
    Brain Pathol; 2014 Jan; 24(1):52-66. PubMed ID: 23941441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
    Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
    Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
    Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
    J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Anaplastic pleomorphic xanthoastrocytoma - single-center analysis of 42 patients].
    Belyaev AY; Shugai SV; Kobyakov GL; Strunina YV; Batalov AI; Pronin IN; Usachev DY
    Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(2):45-54. PubMed ID: 35412712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adult brainstem gliomas: Correlation of clinical and molecular features.
    Theeler BJ; Ellezam B; Melguizo-Gavilanes I; de Groot JF; Mahajan A; Aldape KD; Bruner JM; Puduvalli VK
    J Neurol Sci; 2015; 353(1-2):92-7. PubMed ID: 25934342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
    Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
    J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Characteristics of BRAF V600E Gene Mutation in Patients of Epilepsy-Associated Brain Tumor: a Meta-analysis.
    Xing H; Song Y; Zhang Z; Koch PD
    J Mol Neurosci; 2021 Sep; 71(9):1815-1824. PubMed ID: 33791912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study].
    Zheng LM; Gong J; Zou Y; Zhang MN; Yu TP; Hou J; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):229-235. PubMed ID: 33677887
    [No Abstract]   [Full Text] [Related]  

  • 57. IDH mutations may not preclude distant, trans-tentorial spread in gliomas: a case report and review of the literature.
    Hong CS; Hsieh JK; Edwards NA; Ray-Chaudhury A; Zaghloul KA
    World J Surg Oncol; 2016 Feb; 14():53. PubMed ID: 26911558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
    Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
    Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
    Zhu J; Zuo J; Xu Q; Wang X; Wang Z; Zhou D
    Med Hypotheses; 2011 Apr; 76(4):602-3. PubMed ID: 21284999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
    Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
    Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.